|
1
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Singh S, Hassan D, Aldawsari HM, Molugulu
N, Shukla R and Kesharwani P: Immune checkpoint inhibitors: A
promising anticancer therapy. Drug Discov Today. 25:223–229.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yin Q, Wu L, Han L, Zheng X, Tong R, Li L,
Bai L and Bian Y: Immune-related adverse events of immune
checkpoint inhibitors: A review. Front Immunol.
14(1167975)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Martins F, Sofiya L, Sykiotis GP, Lamine
F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A and
Guex-Crosier Y: Adverse effects of Immune-checkpoint inhibitors:
Epidemiology, management and surveillance. Nat Rev Clin Oncol.
16:563–580. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Poto R, Troiani T, Criscuolo G, Marone G,
Ciardiello F, Tocchetti CG and Varricchi G: Holistic approach to
immune checkpoint inhibitor-related adverse events. Front Immunol.
13(804597)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bass AR, Xie FL, Jannat-Khah D, Ghosh N,
Chan KK, Saxena A and Curtis JR: Incidence of checkpoint
inhibitor-associated inflammatory arthritis, immunomodulation and
mortality in cancer patients on immunotherapy: A retrospective
cohort study. Rheumatology. 64:1637–1642. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cappelli LC, Gutierrez AK, Bingham CO III
and Shah AA: Rheumatic and musculoskeletal immune-related adverse
events due to immune checkpoint inhibitors: A systematic review of
the literature. Arthritis Care Res. 69:1751–1763. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Xie RX, Xue YB, Ci XY and Zhang MJ: Immune
checkpoint inhibitor induced colitis and arthritis: A case report.
Medicine. 102(e36334)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
US Department of Health and Human
Services: Common terminology criteria for adverse events (CTCAE)
version 5.0, 2017.
|
|
10
|
Zheng M, Zhou Y, Zhou J and Jiang Y: 564P
Efficacy and safety of tislelizumab plus anlotinib in the treatment
of cervical cancer resistant to standard therapy: A prospective,
single-arm, open labelled phase II clinical trial. Ann Oncol. 33
(Suppl)(S806)2022.
|
|
11
|
Subedi A, Williams SG, Yao L, Maharjan S,
Strauss J, Sharon E, Thomas A, Apolo AB, Gourh P, Hasni SA, et al:
Use of magnetic resonance imaging to identify immune checkpoint
inhibitor-induced inflammatory arthritis. JAMA Netw Open.
3(e200032)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Abdel-Wahab N and Suarez-Almazor ME:
Frequency and distribution of various rheumatic disorders
associated with checkpoint inhibitor therapy. Rheumatology. 58
(Suppl 7):vii40–vii48. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Melissaropoulos K, Klavdianou K,
Filippopoulou A, Kalofonou F, Kalofonos H and Daoussis D: Rheumatic
manifestations in patients treated with immune checkpoint
inhibitors. Int J Mol Sci. 21(3389)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kostine M, Truchetet ME and Schaeverbeke
T: Clinical characteristics of rheumatic syndromes associated with
checkpoint inhibitors therapy. Rheumatology (Oxford). 58 (Suppl
7):vii68–vii74. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Smith MH and Bass AR: Arthritis after
cancer immunotherapy: Symptom duration and treatment response.
Arthritis Care Res. 71:362–366. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Richter MD, Crowson C, Kottschade LA,
Finnes HD, Markovic SN and Thanarajasingam U: Rheumatic syndromes
associated with immune checkpoint inhibitors: A single-center
cohort of sixty-one patients. Arthritis Rheumatol. 71:468–475.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Johnson DB, Nebhan CA, Moslehi JJ and
Balko JM: Immune-checkpoint inhibitors: Long-term implications of
toxicity. Nat Rev Clin Oncol. 19:254–267. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Braaten TJ, Brahmer JR, Forde PM, Le D,
Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO III and
Shah AA: Immune checkpoint inhibitor-induced inflammatory arthritis
persists after immunotherapy cessation. Ann Rheum Dis. 79:332–338.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gómez-Puerta JA, Lobo-Prat D, Perez-García
C, Ponce A, Frade-Sosa B, Millán Arciniegas AM, Ojeda F,
Ruiz-Esquide V and Corominas H: Clinical patterns and follow-up of
inflammatory arthritis and other immune-related adverse events
induced by checkpoint inhibitors. A multicenter study. Front Med
(Lausanne). 9(888377)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cappelli LC, Brahmer JR, Forde PM, Le DT,
Lipson EJ, Naidoo J, Zheng L, Bingham CO III and Shah AA: Clinical
presentation of immune checkpoint inhibitor-induced inflammatory
arthritis differs by immunotherapy regimen. Semin Arthritis Rheum.
48:553–557. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Paiola M, Portnoy DM, Hao LY, Bukhari S,
Winchester RJ, Henick BS, Mor A and Gartshteyn Y: Osteoarthritis
increases the risk of inflammatory arthritis due to immune
checkpoint inhibitors associated with tissue-resident memory T
cells. J Immunother Cancer. 13(e010758)2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gray-Gaillard EF, Shah AA, Bingham CO III,
Elisseeff JH, Murray J, Brahmer J, Forde P, Anagnostou V, Mammen J
and Cappelli LC: Higher levels of VEGF-A and TNFα in patients with
immune checkpoint inhibitor-induced inflammatory arthritis.
Arthritis Res Ther. 27(74)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen M, Li H, Qu B and Huang X: The roles
of T cells in immune checkpoint inhibitor-induced arthritis. Aging
Dis. 16:2100–2119. 2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang RC, Singaraju A, Marks K, Shakib L,
Dunlap G, Adejoorin I, Greisen SR, Chen L, Tirpack AK, Aude C, et
al: Clonally expanded CD38hi cytotoxic CD8 T cells define the T
cell infiltrate in checkpoint inhibitor-associated arthritis. Sci
Immunol. 8(eadd1591)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhou ZY, Zhou XX, Jiang X, Yang B, Lu X,
Fei YY, Zhao LD, Chen H, Zhang L, Si XY, et al: Single-cell
profiling identifies IL1Bhi macrophages associated with
inflammation in PD-1 inhibitor-induced inflammatory arthritis. Nat
Commun. 15(2107)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Reincke ME, Payne KJ, Harder I, Strohmeier
V, Voll RE, Warnatz K and Keller B: The antigen presenting
potential of CD21low B cells. Front Immunol.
11(535784)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Das R, Bar N, Ferreira M, Newman AM, Zhang
L, Bailur JK, Bacchiocchi A, Kluger H, Wei W and Halaban R: Early B
cell changes predict autoimmunity following combination immune
checkpoint blockade. J Clin Invest. 128:715–720. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Gatto M, Bjursten S, Jonsson CA, Agelii
ML, Jonell C, McGrath S, Lönnblom E, Sareila O, Holmdahl R and
Rudin A: Early increase of circulating transitional B Cells and
autoantibodies to joint-related proteins in patients with
metastatic melanoma developing checkpoint inhibitor-induced
inflammatory arthritis. Arthritis Rheumatol. 75:856–863.
2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Naidoo J, Cappelli LC, Forde PM, Marrone
KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN and Shah AA:
Inflammatory arthritis: A newly recognized adverse event of immune
checkpoint blockade. Oncologist. 22:627–630. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Choi J and Lee SY: Clinical
characteristics and treatment of immune-related adverse events of
immune checkpoint inhibitors. Immune Netw. 20(e9)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Haanen J, Obeid M, Spain L, Carbonnel F,
Wang Y, Robert C, Lyon A, Wick W, Kostine M and Peters S:
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guideline for diagnosis, treatment and follow-up. Ann Oncol.
33:1217–1238. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM and Chau I: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Matas-García A, Milisenda JC,
Selva-O'Callaghan A, Prieto-González S, Padrosa J, Cabrera C,
Reguart N, Castrejón N, Solé M and Ros J: Emerging PD-1 and PD-1L
inhibitors-associated myopathy with a characteristic
histopathological pattern. Autoimmun Rev. 19(102455)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jeyakumar N, Etchegaray M, Henry J,
Lelenwa L, Zhao B, Segura A and Buja LM: The terrible triad of
checkpoint inhibition: A case report of myasthenia gravis,
myocarditis, and myositis induced by cemiplimab in a patient with
metastatic cutaneous squamous cell carcinoma. Case Reports Immunol.
2020(5126717)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Georgios I, Fani S, Dmitrios B, David L
and Dimitrios D: Immune checkpoint inhibitor-induced inflammatory
arthritis vs rheumatoid arthritis: A comparative review. Autoimmun
Rev. 25(103943)2025.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kao CJ, Charmsaz S, Alden SL, Brancati M,
Li HL, Balaji A, Munjal K, Howe K, Mitchell S and Leatherman J:
Immune-related events in individuals with solid tumors on
immunotherapy associate with Th17 and Th2 signatures. J Clin
Invest. 134(e176567)2025.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kwok TSH and Bell MJ: Immune checkpoint
inhibitor-induced rheumatoid arthritis: Insights into an
increasingly common aetiology of polyarthritis. BMJ Case Rep.
12(e227995)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gosangi B, McIntosh L, Keraliya A, Irugu
DVK, Baheti A, Khandelwal A, Thomas R and Braschi-Amirfarzan M:
Imaging features of toxicities associated with immune checkpoint
inhibitors. Eur J Radiol Open. 9(100434)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu Y, Jaquith JM, Mccarthy-Fruin K, Zhu
X, Zhou X, Li Y, Crowson C, Davis JM III, Thanarajasingam U and
Zeng H: Immune checkpoint inhibitor-induced inflammatory arthritis:
A novel clinical entity with striking similarities to seronegative
rheumatoid arthritis. Clin Rheumatol. 39:3631–3637. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ponce A, Frade-Sosa B, Sarmiento-Monroy
JC, Sapena N, Ramírez J, Azuaga AB, Morlà R, Ruiz-Esquide V, Cañete
JD and Sanmartí R: Imaging findings in patients with immune
checkpoint inhibitor-induced arthritis. Diagnostics.
12(1961)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Karlsen W, Akily L, Mierzejewska M,
Teodorczyk J, Bandura A, Zaucha R and Cytawa W: Is 18F-FDG-PET/CT
an optimal imaging modality for detecting immune-related adverse
events after immune-checkpoint inhibitor therapy? Cancers (Basel).
16(1990)2024.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Brahmer JR, Abu-Sbeih H, Ascierto PA,
Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E
and Johnson DB: Society for Immunotherapy of Cancer (SITC) clinical
practice guideline on immune checkpoint inhibitor-related adverse
events. J Immunother Cancer. 9(e002435)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Thompson JA, Schneider BJ, Brahmer J,
Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S
and Davies M: Management of immunotherapy-related toxicities,
version 1.2022, NCCN clinical practice guidelines in oncology. J
Natl Compr Canc Netw. 20:387–405. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kostine M, Finckh A, Bingham CO, Visser K,
Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TR and Cope
AP: EULAR points to consider for the diagnosis and management of
rheumatic immune-related adverse events due to cancer immunotherapy
with checkpoint inhibitors. Ann Rheum Dis. 80:36–48.
2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Hysa E, Casabella A, Iandolino N, Gotelli
E, Genova C, Tanda ET, Pizzorni C, Smith V, Sulli A and Cutolo M:
Clinical outcomes in cancer patients with immune checkpoint
inhibitor-induced arthritis treated with methotrexate: A
retrospective longitudinal monocentric pilot study. Clin Exp
Rheumatol. 43:867–873. 2025.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Bass AR, Abdel-Wahab N, Reid PD, Sparks
JA, Calabrese C, Jannat-Khah DP, Ghosh N, Rajesh D, Aude CA and
Gedmintas L: Comparative safety and effectiveness of TNF
inhibitors, IL6 inhibitors and methotrexate for the treatment of
immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis.
82:920–926. 2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Petit PF, Daoudlarian D, Latifyan S,
Bouchaab H, Mederos N, Doms J, Abdelhamid K, Ferahta N, Mencarelli
L and Joo V: Tocilizumab provides dual benefits in treating immune
checkpoint inhibitor-associated arthritis and preventing relapse
during ICI rechallenge: The TAPIR study. Ann Oncol. 36:43–53.
2025.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Abe K, Ishikawa Y, Fujiwara M, Yukawa H,
Yanagihara T, Takei S, Arioka H and Kita Y: Immune checkpoint
inhibitor-induced refractory polyarthritis rapidly improved by
sarilumab and monitoring with joint ultrasonography: A case report.
Medicine (Baltimore). 101(e28428)2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ma VT, Lao CD, Fecher LA and Schiopu E:
Successful use of secukinumab in two melanoma patients with immune
checkpoint inhibitor-induced inflammatory arthropathy.
Immunotherapy. 14:593–598. 2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Liu Q, Liu M, Zou Z, Lin J, Zhang N, Zhao
L, Zhou J, Zhou H, Zhou X and Jiao X: Tofacitinib for the treatment
of immune-related adverse events in cancer immunotherapy: A
multi-center observational study. J Transl Med.
22(803)2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Murray K, Floudas A, Murray C, Fabre A,
Crown J, Fearon U and Veale D: First use of tofacitinib to treat an
immune checkpoint inhibitor-induced arthritis. BMJ Case Rep.
14(e238851)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Berg MHH, Del Rincón SV and Miller WH:
Potential therapies for immune-related adverse events associated
with immune checkpoint inhibition: From monoclonal antibodies to
kinase inhibition. J Immunother Cancer. 10(e003551)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Ma X, Liu B, Fan L, Liu Y, Zhao Y, Ren T
and Li Y and Li Y: Native and engineered exosomes for inflammatory
disease. Nano Res. 16:6991–7006. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kostine M, Rouxel L, Barnetche T, Veillon
R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S and
Beylot-Barry M: Rheumatic disorders associated with immune
checkpoint inhibitors in patients with cancer-clinical aspects and
relationship with tumour response: A single-centre prospective
cohort study. Ann Rheum Dis. 77:393–398. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Verspohl SH, Holderried T, Behning C,
Brossart P and Schäfer VS: Prevalence, therapy and tumour response
in patients with rheumatic immune-related adverse events following
immune checkpoint inhibitor therapy: A single-centre analysis. Ther
Adv Musculoskelet Dis. 13(1759720X211006963)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ladouceur A, Barnetche T, Prey S, Dutriaux
C, Gerard É, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R and
Domblides C: Resolution of immune checkpoint inhibitors-induced
inflammatory arthritis while maintaining active treatment with
checkpoint inhibitors and after its discontinuation: An
observational study. Joint Bone Spine. 92(105795)2025.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Thompson JA, Schneider BJ, Brahmer J,
Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M,
Dunnington D, et al: NCCN guidelines insights: Management of
immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc
Netw. 18:230–241. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Park R, Lopes L and Saeed A: Outcomes
following immunotherapy re-challenge after immune-related adverse
event: Systematic review and meta-analysis. Immunotherapy.
12:1183–1193. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ladouceur A, Barnetche T, Mouterde G,
Tison A, Bitoun S, Prey S, Dutriaux C, Gerard E, Pham-Ledard A,
Beylot-Barry M, et al: Immune checkpoint inhibitor rechallenge in
patients who previously experienced immune-related inflammatory
arthritis: A multicentre observational study. RMD Open.
9(e003795)2023.PubMed/NCBI View Article : Google Scholar
|
![FDG PET/CT scan of case 3 and
representative fused PET/CT images showing polyarticular and
periarticular FDG uptake, consistent with immune checkpoint
inhibitor-induced inflammatory arthritis. (A) Whole-body
musculoskeletal FDG uptake imaging. (B) Bilateral shoulder joints
and periarticular soft tissues. (C) Bilateral elbow joints. (D)
Bilateral hip joints. (E) Bilateral knees and surrounding soft
tissues, depicting a small amount of joint effusion within the knee
cavities. (F) Bilateral ankle joints and periarticular soft
tissues, showing swelling. In panel A, the red arrows indicate
representative sites of abnormal periarticular FDG uptake. In
panels B-F, the crosses indicate the representative joints/regions
shown on the corresponding fused PET/CT images. FDG,
2-deoxy-2-[18F]fluoro-D-glucose; PET/CT, positron
emission tomography-computed tomography.](/article_images/etm/32/2/etm-32-02-13196-g03.jpg)
